期刊文献+

结直肠癌肝转移的新辅助治疗进展 被引量:3

Advance in neoadjuvant chemotherapy for colorectal liver metastasis
原文传递
导出
摘要 目前,新辅助治疗已逐步应用到结直肠癌肝转移的治疗模式中。临床研究表明,新辅助化疗、新辅助放疗和新辅助放化疗可提高结直肠癌肝转移的手术切除率和根治性,对中下段直肠癌可术前降期、提高手术切除率、保肛率和降低复发率。新辅助治疗在结直肠癌肝转移综合治疗中具有较大的临床应用价值。 Neoadjuvant therapy has been gradually applied to the treatment of colorectal liver metasta- sis in recent years. Many clinic researches indicate neoadjuvent chemotherapy, neoadjuvent radiotherapy and neoadjuvent chemoradiotherapy can improve surgical reaction rate and radical rate of colorectal liver metastasis, and can shrink the primary tumor and metastasis, improve the resection rate and sphincter preservation rate, and reduce the recurrence rate of locally advanced lower rectal cancer. Neoadjuvent therapy has great clinical practical value in the muhi-modality treatment for colorectal metastasis.
出处 《国际肿瘤学杂志》 CAS 2010年第11期859-862,共4页 Journal of International Oncology
关键词 结直肠肿瘤 肿瘤转移 肿瘤辅助治疗 放射疗法 Colorectal neoplasms Neoplasm Metastasis Neoadjuvent therapy Radiotherapy
  • 相关文献

参考文献5

二级参考文献47

共引文献40

同被引文献46

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[J]. CA Cancer J Clin, 2012, 62(1): 10-29.
  • 2Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan- European consensus on the treatment of patients with colorectal liver metastases[J]. Eur J Cancer, 2006, 42(14): 2212-2221.
  • 3Dawood O, Mahadevan A, Goodman KA. Stereotactic body radiation therapy for liver metastases[J]. Eur J Cancer, 2009, 45(17): 2947-2959.
  • 4Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases[J]. Ann Surg, 2005, 241(5): 722-724.
  • 5Tsai MS, Su YH, Ho MC, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous eolorectal liver metastasis[J]. Ann Surg Oncol, 2007, 14(2): 786-794.
  • 6Abdalla EK. Commentary: Radiofrequency ablation for eolorectal liver metastases: do not blame the biology when it is the technology[J]. Am J Surg, 2009, 197(6): 737-739.
  • 7Falcone A, Ricci S, Brunetti I, et al. Phase Ⅲ trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusianal fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest[J]. J Clin Oncol, 2007, 25(13): 1670-1676.
  • 8Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinie acid, 5-tluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) asfirst-line treatment in metastatic colorectal cancer (MCC): a multicenlre randomised phase III trial from the Hellenic Oncology Research Group (HORG)[J]. Br J Cancer, 2006, 94(6): 798-805.
  • 9Masi G, Vasile E, Loupakis F, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis[J]. J Natl Cancer Inst, 2011, 103(1): 21-30.
  • 10Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial[J]. Lancet Oncol, 2010, 11(1): 38-47.

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部